C.Q.Pharmaceutical Holding Co.Ltd(000950) it was announced on January 6 that in order to optimize the asset liability structure of Chongqing pharmaceutical (Group) Co., Ltd. (“Chongqing pharmaceutical Co., Ltd.”), its main holding subsidiary, further enhance its capital strength and promote the rapid development of business, the company invested 400 million yuan in cash to increase its capital. After the capital increase, the total share capital of Chongqing pharmaceutical Co., Ltd. changed to about 471 million yuan, and the shareholding ratio of the company increased to 99.95%.
According to the data, as of December 31, 2020, the audited total assets of heavy Pharmaceutical Co., Ltd. were RMB 41.533 billion, the net assets were RMB 9.019 billion, and the asset liability ratio was 78.28%; As of September 30, 2021, the asset liability ratio was 79.38%. From January to September 2021, the operating revenue was 46.219 billion yuan, with a year-on-year increase of 51.96%. With the rapid growth of sales revenue, it brought a large demand for working capital.
It is understood that the capital increase comes from C.Q.Pharmaceutical Holding Co.Ltd(000950) own funds. After receiving the capital increase funds, Chongqing pharmaceutical Co., Ltd. plans to use them for daily operation. The governance structure of Chongqing pharmaceutical Co., Ltd. remained unchanged before and after the capital increase.
C.Q.Pharmaceutical Holding Co.Ltd(000950) said that the capital increase will help to improve the asset liability structure of Chongqing Heavy Pharmaceutical Co., Ltd., improve its profitability and market competitiveness, so as to meet the needs of business development, continuously and steadily improve business advantages and ensure the realization of strategic objectives.
According to the latest financial data, the operating revenue of C.Q.Pharmaceutical Holding Co.Ltd(000950) in the first three quarters of 2021 was 46.219 billion yuan, a year-on-year increase of 51.95%; The net profit attributable to the parent company was 682 million yuan, with a year-on-year increase of 11.40% and earnings per share of 0.39 yuan.
(Shanghai Securities News · China Securities Network)
